home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Kezar Life Sciences, Inc. - Common Stock (NQ:KZR)

7.370 +0.020 (+0.27%)

Streaming Delayed Price Updated: 4:00 PM EDT, Apr 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Kezar Life Sciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Week In Review: Mabwell Sells Ex-China Rights To Rare Disease Therapy In $412 Million Deal ↗

March 02, 2024

Mabwell, a Shanghai-San Diego biotech, sold ex-China rights for 9MW3011 to Disc Medicine of Watertown, MA in a deal worth up to $412 million. Meanwhile, AstraZeneca has returned most of the global...

Via Talk Markets

Kezar Life Sciences to Participate in the TD Cowen 44th Annual Health Care Conference

February 28, 2024

From Kezar Life Sciences, Inc.

Via Business Wire

Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis

February 26, 2024

From Kezar Life Sciences, Inc.

Via Business Wire

3 Top Penny Stocks for 5,000% Upside in 2024 and Beyond ↗

February 25, 2024

When you want to light your afterburners, these ideas will do the trick.

Via InvestorPlace

Analyst Expectations for Kezar Life Sciences's Future ↗

November 27, 2023

Via Benzinga

3 Penny Stocks Poised for an Unbelievable 1,000% Jump ↗

February 02, 2024

Discover penny stocks with the potential for a 1,000% leap: strategic growth, debt-free stability and pharmaceutical innovation await.

Via InvestorPlace

As Oversupply Deflates Lithium Bubble, IPO Market Keeps In High Spirits ↗

January 08, 2024

Lithium market facing persistent turmoil as spot prices decline for more than a year. But asset management firm Janus Henderson sees a silver lining.

Via Benzinga

Topics Initial Public Offering

Bull Run Bonanza: Top 3 Penny Stocks Primed for Explosive Growth ↗

December 18, 2023

Are you looking for the next bull run bonanza? Here are the top three penny stocks primed for explosive growth.

Via InvestorPlace

Kezar Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update

November 13, 2023

From Kezar Life Sciences, Inc.

Via Business Wire

Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

November 03, 2023

From Kezar Life Sciences, Inc.

Via Business Wire

10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis

October 23, 2023

Via ACCESSWIRE

Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

October 09, 2023

From Kezar Life Sciences, Inc.

Via Business Wire

Kezar Life Sciences Announces Strategic Restructuring to Prioritize Clinical-Stage Assets and Extend Financial Runway and Appoints Christopher Kirk, Ph.D. as Chief Executive Officer

October 03, 2023

From Kezar Life Sciences, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For October 5, 2023 ↗

October 05, 2023

Via Benzinga

Week In Review: Everest Acquires Novel Autoimmune Therapy In $132 Million Agreement ↗

September 23, 2023

Shanghai Everest Medicines acquired China/Asian rights to a novel therapy for autoimmune diseases from Kezar Life Sciences of South San Francisco in a deal worth $132.5 million. The company will make...

Via Talk Markets

Why Murphy Canyon Acquisition Shares Are Trading Higher By Around 32%; Here Are 20 Stocks Moving Premarket ↗

September 21, 2023

Gainers Near Intelligence, Inc. (NASDAQ: NIR) shares rose 34.1% to $0.2801 in pre-market trading after falling 42% on Wednesday. Near Intelligence recently named its General Counsel, Jay Angelo, to...

Via Benzinga

Kezar Life Sciences and Everest Medicines Enter into an Agreement to Develop and Commercialize Zetomipzomib for Lupus Nephritis and other Potential Indications in Greater China, South Korea and Southeast Asia

September 20, 2023

From Kezar Life Sciences, Inc.

Via Business Wire

Kezar Life Sciences to Participate in Three Upcoming Investor Conferences

August 31, 2023

From Kezar Life Sciences, Inc.

Via Business Wire

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

August 22, 2023

Via Benzinga

Top 5 Health Care Stocks That Could Blast Off This Month ↗

August 21, 2023

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

August 15, 2023

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

August 11, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 11, 2023 ↗

August 11, 2023

Via Benzinga

Why Maxeon Solar Technologies Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

August 11, 2023

Gainers Amyris, Inc. (NASDAQ: AMRS) shares jumped 179.1% to $0.1839. Amyris shares dipped over 80% on Thursday after the company announced it filed for Chapter 11 bankruptcy.

Via Benzinga

Topics Bankruptcy

Kezar Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business Update

August 10, 2023

From Kezar Life Sciences, Inc.

Via Business Wire

Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

August 04, 2023

From Kezar Life Sciences, Inc.

Via Business Wire

Stocks That Hit 52-Week Lows On Thursday ↗

July 27, 2023

During Thursday, 56 stocks hit new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

July 25, 2023

On Tuesday, 56 companies set new 52-week lows.

Via Benzinga

Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

July 07, 2023

From Kezar Life Sciences, Inc.

Via Business Wire

Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

June 09, 2023

From Kezar Life Sciences

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com